iAnthus Announces Licensing Agreement with Women-Focused Infused Products Brand, Blissiva
NEW YORK and TORONTO, April 4, 2019 /PRNewswire/ – iAnthus Capital Holdings, Inc. (“iAnthus” or the “Company”) (CSE: IAN, OTCQX: ITHUF), which owns, operates, and partners with best-in-class regulated cannabis operations across the United States, is pleased to announce a licensing agreement entered into between its U.S. subsidiary and Blissiva, a women-owned, Maryland-based company specializing in producing and distributing medical cannabis products specifically formulated for women. As per the licensing agreement, iAnthus will manufacture, market and sell a variety of Blissiva products in its markets, with initial launch in Maryland scheduled for April 20, 2019. Additionally, iAnthus has the exclusive right to launch Blissiva in its ten other existing states and across the United States.
Blissiva was founded by obstetrician gynecologist Dr. Leslie Apgar and serial entrepreneur Gina Dubbé who have a mission to make medical cannabis more accessible and desirable to women. Blissiva’s first product, the Balance Pen, was formulated specifically to help women combat stress and anxiety. The pen first came to market in October 2018 and sold out in just six weeks of its anticipated 12 week run. Blissiva is developing a line of additional products designed for women’s health, wellness and recreation.
We are extremely proud to partner with Blissiva in launching female-focused cannabis products into the market. Women represent one of the largest and fastest growing demographics of consumers in this industry, and there is currently a lack of products specifically designed to address their health and wellness needs.
Beth Stavola, Chief Strategy Officer of iAnthus
We believe that women should be able to ‘have it all,’ and I’m excited to be working with Dr. Apgar, a groundbreaking expert in women’s health, to fill the gap in the industry.
iAnthus intends to initially launch the Blissiva Balance Pen in Health for Life dispensaries in Baltimore, Bethesda and White Marsh, Maryland, as well as the Greenhouse Wellness dispensary in Ellicott City, Maryland, where Dr. Apgar is the medical director. Additionally, iAnthus will leverage its distribution network to provide women with access to Blissiva products throughout the state. Currently, this Maryland distribution network consists of 45 dispensaries where iAnthus is currently selling its MPX branded products.
We believe that iAnthus is the perfect partner to realize our goal of reaching female consumers who could benefit from our products across the country. With iAnthus’ production capabilities and sizable distribution network in key markets, we are confident that together we will be successful in creating a national brand—by women, for women.
Dr. Apgar, Co-Founder and Medical Director of Blissiva
About iAnthus Capital Holdings, Inc.
iAnthus Capital Holdings, Inc. owns and operates best-in-class licensed cannabis cultivation, processing and dispensary facilities throughout the United States, providing investors diversified exposure to the U.S. regulated cannabis industry. Founded by entrepreneurs with decades of experience in operations, investment banking, corporate finance, law and health care services, iAnthus provides a unique combination of capital and hands-on operating and management expertise. iAnthus currently has operations in 11 states, and operates 21 dispensaries (AZ-4, MA-1, MD-3, FL-3, NY-2, CO-1, VT-1 and NM-6 where iAnthus has minority ownership). For more information, visit www.iAnthusCapital.com.
About Blissiva
Blissiva, founded by Gina Dubbé and Dr. Leslie Apgar, is a women-owned, Maryland-based company specializing in producing and distributing medical cannabis products specifically formulated for women. The company’s first product, the Balance Pen, was created to help women combatting anxiety find relief in a safe, holistic, and approachable way. Other product lines are set to launch in 2019. The company’s tagline “Gyno-Created, Goddess-Approved” is a nod to the company’s founders and the medical viability of the product. For more information, visit www.blissiva.com.
